Skip to content

Fructose-driven urate production

Gout weakness

Ketohexokinase (KHK, fructokinase) consumes ATP while phosphorylating fructose. Under a sufficiently strong fructose load, ATP and phosphate depletion can increase AMP turnover through AMP deaminase; the pre-existing adenine nucleotide pool is then degraded through IMP, inosine, hypoxanthine, xanthine, and urate. KHK-dependent ATP loss and urate generation have been measured in human proximal-tubule cells (In Vitro; PMID 19158351).

fructose
  ↓ KHK consumes ATP
fructose-1-phosphate + ADP
  ↓ ATP/phosphate depletion
AMP → IMP → inosine → hypoxanthine → xanthine → urate

This is purine catabolism, not creation of new purines through de-novo synthesis. PRPS supplies PRPP to de-novo purine synthesis, purine salvage, and pyrimidine synthesis; the current evidence does not establish that fructose-driven urate production works by relieving PRPS inhibition or increasing PRPP supply. See PRPS / PRPP supply.

SLC2A9 / GLUT9 boundary

SLC2A9 is a major renal urate transporter. Homozygous loss-of-function mutations impair urate reabsorption and cause severe renal hypouricemia, often with very high fractional urate excretion and risks including nephrolithiasis and exercise-induced acute kidney injury (Human Observational + In Vitro; PMID 19926891).

Therefore:

  • SLC2A9 loss-of-function is not evidence of impaired urate excretion or increased hyperuricemia risk.
  • A common-variant association at the SLC2A9 locus does not specify the direction of an individual's transporter function.
  • The historic claim that GLUT9 creates a two-way fructose-and-urate genetic vulnerability is not decision-usable. Fructose transport, renal urate reabsorption, and KHK-driven metabolism require separate measurements.
  • SLC2A9 genotype does not justify a KHK intervention, a dietary rule, or a fructose challenge.

The canonical variant direction belongs in gout genetic variants.

KHK as an experimental intervention

PF-06835919 provides a defined KHK-inhibitor precedent. It has been evaluated in preclinical systems and in human metabolic-disease studies (Animal Model + Clinical Trial; PMID 32910646, PMCID PMC8050029, and DOI 10.1111/dom.14946). Those studies establish that KHK can be pharmacologically engaged; they do not establish gout efficacy, a serum-urate effect in gout, or a clinical use rule.

A gout-relevant KHK experiment must keep these readouts separate:

  1. target engagement and fructose-1-phosphate formation;
  2. ATP and phosphate depletion;
  3. AMP turnover and isotope-resolved purine catabolism;
  4. urate production and mass balance;
  5. off-target transporter and metabolic effects; and
  6. viability and recovery after exposure.

The relevant evidence object is a compositionally verified inhibitor at a measured free exposure. A dietary ingredient, botanical extract, docking hit, or predicted KHK binder cannot inherit PF-06835919's evidence.

Possible intestinal feed-forward loop

Rat ileal evidence and KHK-dependent intestinal-cell evidence motivate a second question: could fructose-associated KHK/ROS signaling reduce functional intestinal ABCG2 urate export while KHK-driven metabolism increases urate production? The complete causal chain and its relevance to human gout remain unmeasured.

Research conjecture — fructose can raise urate while narrowing intestinal export

Grounded premises: KHK-dependent fructose metabolism can consume ATP and generate urate in human proximal-tubule cells (In Vitro; PMID 19158351). Rat ileal and intestinal-cell work motivates a NOX/ROS–ABCG2 link (Animal Model + In Vitro; source and assay boundary in validation §1.39).

Novel leap: The two arms might operate together, so the same exposure increases urate production while reducing intestinal urate export. No direct evidence tests the complete chain in a human intestinal system.

Why it matters: A coupled result would expose a feed-forward weakness and distinguish a production-only intervention from one that must also preserve gut urate transport.

Discriminating observation: In polarized human ileal enteroids, compare matched fructose and glucose conditions with KHK and NOX perturbations. Measure ATP, ROS, ABCG2 surface state, directional urate flux, and viability. Advance the conjecture only if the perturbations separate KHK-dependent ATP loss from NOX/ABCG2-dependent flux loss.

Falsification program

  • Production arm: Use isotope-resolved fructose and purine measurements to test whether KHK inhibition changes urate production under a defined exposure. A change in serum or media urate without mass balance does not locate the mechanism.
  • Export arm: Run validation §1.39. A high-dose toxicity result, expression-only change, or nondirectional transporter assay does not support the feed-forward loop.
  • PRPP arm: Measure PRPP and de-novo/salvage flux directly before assigning a PRPS mechanism. The AMP-catabolism result does not imply it.
  • Genetic arm: Use isogenic SLC2A9 models only for a specified urate- transport question. Do not infer fructose sensitivity from risk-locus status.

A negative result narrows the tested exposure, compartment, and mechanism; it does not erase fructose-driven AMP catabolism or other KHK-dependent disease biology.